Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA.
作者信息
Della Corte C M, Morgillo F
机构信息
Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
出版信息
ESMO Open. 2021 Feb;6(1):100041. doi: 10.1016/j.esmoop.2020.100041. Epub 2021 Jan 18.
Abstract
摘要
相似文献
1
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA.
ESMO Open. 2021 Feb;6(1):100041. doi: 10.1016/j.esmoop.2020.100041. Epub 2021 Jan 18.
2
Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Drugs Today (Barc). 2021 Oct;57(10):621-629. doi: 10.1358/dot.2021.57.10.3313852.
3
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers.
Ann Surg Oncol. 2024 Apr;31(4):2202-2203. doi: 10.1245/s10434-023-14854-w. Epub 2024 Jan 20.
4
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: 10.1016/S1470-2045(22)00541-1. Epub 2022 Sep 12.
5
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with Gene Mutations or Fusions.
Clin Cancer Res. 2021 Apr 15;27(8):2130-2135. doi: 10.1158/1078-0432.CCR-20-3558. Epub 2020 Nov 25.
6
Selpercatinib: First Approval.
Drugs. 2020 Jul;80(11):1119-1124. doi: 10.1007/s40265-020-01343-7.
7
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Ann Oncol. 2021 Feb;32(2):261-268. doi: 10.1016/j.annonc.2020.10.599. Epub 2020 Nov 5.
8
Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1117-1122. doi: 10.1080/14737140.2023.2267754. Epub 2023 Oct 27.
9
Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1833-1834. doi: 10.1007/s00259-022-06061-8. Epub 2022 Dec 16.
10
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Clin Cancer Res. 2021 Jan 1;27(1):34-42. doi: 10.1158/1078-0432.CCR-20-2278. Epub 2020 Oct 20.
引用本文的文献
1
Systemic Therapeutic Options in Radioiodine-Refractory Differentiated Thyroid Cancer: Current Indications and Optimal Timing.
Cancers (Basel). 2025 May 28;17(11):1800. doi: 10.3390/cancers17111800.
2
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer.
Front Oncol. 2025 Jan 27;14:1497093. doi: 10.3389/fonc.2024.1497093. eCollection 2024.
3
Selpercatinib in Chinese patients with -fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial.
Ther Adv Med Oncol. 2025 Jan 1;17:17588359241307199. doi: 10.1177/17588359241307199. eCollection 2025.
4
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Cell Commun Signal. 2024 Sep 28;22(1):460. doi: 10.1186/s12964-024-01837-x.
5
Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.
Thyroid Res. 2023 Aug 14;16(1):22. doi: 10.1186/s13044-023-00166-4.
6
A comprehensive overview of the relationship between RET gene and tumor occurrence.
Front Oncol. 2023 Feb 14;13:1090757. doi: 10.3389/fonc.2023.1090757. eCollection 2023.
7
Targeted therapy of RET fusion-positive non-small cell lung cancer.
Front Oncol. 2022 Dec 13;12:1033484. doi: 10.3389/fonc.2022.1033484. eCollection 2022.
8
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.
Cancers (Basel). 2022 Oct 27;14(21):5298. doi: 10.3390/cancers14215298.
9
Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.
Virchows Arch. 2022 Sep;481(3):351-366. doi: 10.1007/s00428-022-03344-1. Epub 2022 Jul 20.
10
Research Progress on RET Fusion in Non-Small-Cell Lung Cancer.
Front Oncol. 2022 May 30;12:894214. doi: 10.3389/fonc.2022.894214. eCollection 2022.
本文引用的文献
1
Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Drugs Today (Barc). 2021 Oct;57(10):621-629. doi: 10.1358/dot.2021.57.10.3313852.
2
Efficacy of Selpercatinib in -Altered Thyroid Cancers.
N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651.
3
Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653.
4
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.
5
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Lancet Respir Med. 2017 Jan;5(1):42-50. doi: 10.1016/S2213-2600(16)30322-8. Epub 2016 Nov 4.
6
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559.
7
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.
8
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24.
9
Cabozantinib in progressive medullary thyroid cancer.
J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3.
10
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24.
Zotero 插件